iTeos Therapeutics
ITOS
ITOS was delisted on the 28th of August, 2025.
138 hedge funds and large institutions have $537M invested in iTeos Therapeutics in 2024 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 50 increasing their positions, 44 reducing their positions, and 19 closing their positions.
16% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 19
14% more capital invested
Capital invested by funds: $471M → $537M (+$65.5M)
14% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 44
3.72% more ownership
Funds ownership: 96.41% → 100.13% (+3.7%)
1% more funds holding
Funds holding: 136 → 138 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
57% less call options, than puts
Call options by funds: $9.69M | Put options by funds: $22.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$25.1M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$17.9M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$16.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.87M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$7.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$15.9M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$12.9M |
| 3 |
Millennium Management
New York
|
-$9.19M |
| 4 |
Morgan Stanley
New York
|
-$7.78M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$6.75M |
ITOS Hedge Fund Activity: Q2 2024 in Review
138 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q2 2024, worth a combined $537M — up 14% from $471M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ITOS positions and 19 closed out — a net gain of 3 holders — while 50 added to existing stakes and 44 trimmed.
The largest buyer was Vestal Point Capital, opening a new position worth an estimated $25.1M. The largest seller was Braidwell, exiting entirely with an estimated $15.9M sold.
- 138 institutional investors held iTeos Therapeutics (ITOS) as of Q2 2024, up from 136 in Q1 2024.
- Funds reported $537M of iTeos Therapeutics stock for Q2 2024, up 14% quarter-over-quarter.
- 22 funds opened new iTeos Therapeutics positions in Q2 2024 and 19 closed out, a net change of +3 holders.
- The largest iTeos Therapeutics buyer in Q2 2024 was Vestal Point Capital, an estimated $25.1M added.
- The largest iTeos Therapeutics seller in Q2 2024 was Braidwell, an estimated $15.9M sold.
Based on aggregated 13F filings for Q2 2024.